Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Tumor Lysis Syndrome 1Hematologic Neoplasms 1

Interventions

Specimen Handling 631pembrolizumab 610Magnetic Resonance Spectroscopy 553Carboplatin 450Cisplatin 398Cyclophosphamide 397Biopsy 375Nivolumab 326Paclitaxel 324Gemcitabine 317Radiotherapy 286Bevacizumab 244Dexamethasone 222fludarabine 215Docetaxel 199durvalumab 195venetoclax 188Oxaliplatin 187atezolizumab 184Fluorouracil 177Rituximab 176Pemetrexed 173Capecitabine 169Radiation 167Doxorubicin 166Radiosurgery 159Ipilimumab 147Etoposide 142Leucovorin 141Lenalidomide 139

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Carbamates × 90 days × Clear all
NCT04745910 2026-05-06

Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome

M.D. Anderson Cancer Center

Phase 4 Completed
10 enrolled
Other hematologic neoplasm

Tumor Lysis Syndrome, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡